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In this paper the Working Group on Myocardial and Pericardial Disease proposes a revised definition of dilated cardiomyopathy (DCM) in an
attempt to bridge the gap between our recent understanding of the disease spectrum and its clinical presentation in relatives, which is key for
early diagnosis and the institution of potential preventative measures. We also provide practical hints to identify subsets of the DCM syndrome
where aetiology directed management has great clinical relevance.
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Introduction
Research over recent decades has shed new light on the aetiology
and natural history of dilated cardiomyopathy (DCM).1 –8 In particu-
lar, it is recognized that many patients have a long preclinical phase
characterized by few if any symptoms and minor cardiac abnormal-
ities that fall outside current disease definitions.1,2,5,9 – 12 It is also
clear that distinct subtypes in fact share a common DCM pheno-
type.13– 19 The aim of this position paper was to update the defini-
tion of DCM to take into account its diverse aetiology and clinical
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manifestations in patients and relatives. We do not describe the
general management of left ventricular systolic dysfunction as this
is covered in existing European Society of Cardiology (ESC) heart
failure guidelines20 but do consider the implications of an aetiology
oriented approach to therapy.
Causes of dilated cardiomyopathy
Dilated cardiomyopathy is currently defined by the presence of left
ventricular (LV) or biventricular dilatation and systolic dysfunction in
the absence of abnormal loading conditions (hypertension, valve
disease) or coronary artery disease sufficient to cause global systolic
impairment.5 The causes of DCM can be classified as genetic or
non-genetic5 (Table 1), but there are circumstances in which genetic
predisposition interacts with extrinsic or environmental factors.
Genetic causes
Large population studies report an increased risk of disease in the
offspring of patients with non-ischaemic heart failure similar to
that seen in other complex genetic traits.21 Dilated cardiomyopathy
can also appear to be inherited as a monogenic trait with autosomal-
dominant, X-linked, autosomal-recessive, and matrilinear modes of
transmission.1,2,5,22 –24 In the pre-molecular era, systematic cardiac
screening of the relatives of patients with DCM identified probable
familial disease in about 20–35% of cases.11,24,25 Subsequently,
more than 50 disease-related genes have been reported (main genes
in Table 1),7 although relatively few are supported by robust segre-
gation analyses or experimental data. Sequencing studies using small
and medium size panels of genes identify potentially causative muta-
tions in about 20–25% of affected cases, with lamin A/C and cardiac
sarcomere genes the most frequently reported.26,27 With the ad-
vent of high-throughput low-cost sequencing technologies, analysis
of many more genes, including large genes such as titin, has become
feasible28 and suggests that mutations in TTN are most frequent in
DCM,29 although it remains to be confirmed that truncating muta-
tions in TTN are always pathogenic.
Increasingly, studies using high-throughput platforms report the
presence of more than one potentially causative mutation in patients
with DCM.30 While many are probably silent variants, a new model of
oligogenic inheritance (i.e. a disease caused by a small number of mu-
tations in more than one gene) is emerging that poses considerable
challenges for genetic counselling and predictive testing. This may
provide one explanation for the sometimes dramatic variation in dis-
ease penetrance seen in some individual families. From a clinical per-
spective, careful phenotypic evaluation of patients and their families is
crucial for the correct interpretation of genetic results.30
Non-genetic causes
Drugs and toxins
A number of chemical compounds can induce DCM, the most com-
mon of which are excess alcohol consumption and chemotherapeutic
agents (see Table 1 and Supplementary material online, Table S1).
Alcoholic cardiomyopathy is often overlooked and suggested in
some studies to account for 21–32% of DCM (reviewed in ref.
31). Alcohol causes LV systolic dysfunction in a dose-related manner
and some studies suggest reversibility upon abstention. Other
toxins can cause immediate LV dysfunction or many years after
exposure. It often resolves following withdrawal of the drug or tox-
in, but can persist for many years in a subclinical form. In the case of
alcohol and some drugs such as anthracylines, there appears to be
individual susceptibility that relates to genetic and non-genetic
mechanisms.
Myocarditis
Myocarditis is a recognized cause of DCM and the current state of
knowledge on aetiology, diagnosis, management, and therapy of
myocarditis has been summarized in a recently published position
statement.30 The diagnosis of myocarditis is based on a suspicious
clinical presentation combined with endomyocardial biopsy (EMB)
confirmation (by histology, immunohistology, and molecular evi-
dence for infection). Biopsy-proven myocarditis may be reversible
if the acute inflammatory process heals and the cause (for example,
viral infection) resolves, but in up to 30% of cases it can progress to
DCM.3 In a proportion of familial and non-familial pedigrees,
infection-negative myocarditis, with or without a DCM phenotype,
is an organ-specific autoimmune disease occurring in genetically
predisposed individuals.9 In such cases, symptom-free relatives
may exhibit serum organ-specific anti-heart antibodies (AHA),9 –11
that are associated with more frequent mild left ventricular
abnormalities and predict progression to DCM.9 –11
Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a rare but potentially life-
threatening disorder defined by the development of unexplained
systolic heart failure towards the end of pregnancy or in the months
following delivery.32 A number of associations are reported in-
cluding Afro-Caribbean ethnicity, older age, multiparity, multiple
pregnancy, and hypertension with or without pre-eclampsia. The
aetiology is complex and includes autoimmunity, foetal microchi-
merism, virus infection, stress activated cytokines and toxicity
caused by an abnormal cleavage product of prolactin (recently
reviewed in ref. 33). As in other apparently acquired causes of
DCM, genetic predisposition seems important in some cases, with
a recent report of familial DCM co-existing with PPCM or identifi-
cation of DCM causative mutations in some PPCM women.19
Combined effects
The above aetiologies may occur in combination, e.g. patients with
myocarditis may have excessive alcohol intake or pathogenic
mutations. This is likely to aggravate the resulting DCM phenotype.
Thus a patient with genetic DCM may benefit from removal of any
environmental factor that burdens the susceptible myocardium.
Proposed diagnostic criteria
While the existing definition of DCM has served well, it has a num-
ber of important limitations. Most notable is the fact that the term
encompasses a broad range of genetic and acquired disorders that
manifest as a spectrum of electrical and functional abnormalities that
change with time. This applies particularly to genetic diseases that
have delayed or incomplete cardiac expression, with the result
that many mutation carriers have intermediate phenotypes that
do not meet standard disease definitions.8,34 Similarly, systolic LV
dysfunction or dilatation in acquired diseases such as myocarditis
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Table 1 Aetiologies of dilated cardiomyopathy
Group Subtype disease or agent Comments
Genetics
Main genes associated with
predominant cardiac
phenotype:
Titin (TTN) 20–25% of familial DCM; autosomal-dominant (AD) mode
Lamin A/C (LMNA) 6%; AD mode; associated with AVB and VA; can also cause
Limb-Girdle myopathy
Myosin heavy chain (MYH7) 4%; AD mode
Troponin T (TNNT2) 2%; AD mode
Myosin-binding protein C (MYBPC3) 2%; AD mode
RNA-binding Motif-20 (RBM20) 2%; AD mode
Myopalladin (MYPN) 2%; AD mode
Sodium channel alpha unit (SCN5A) 2%; AD mode
BaCl2-associated athanogene 3 (BAG3) 2%; AD mode
Phospholamban (PLN) 1%; AD mode; low QRS voltage on ECG
Neuromuscular disorders
Duchenne muscular dystrophy (DMD) X-linked mode; CK elevation; paediatric patients
Becker muscular dystrophy (BMD) X-linked mode; CK elevation; paediatric or adult patients
Myotonic dystrophy or Steinert (MD) AD mode; AV block
Syndromic diseases
Mitochondrial diseases Mitochondrial inheritance syndromic expression including
skeletal myopathy
Tafazin (TAZ/G4.5) X-linked mode; paediatric patients; Barth syndrome
Drugs
Antineoplastic drugs Anthracyclines; antimetabolites; alkylating agents; Taxol;
hypomethylating agent; monoclonal antibodies; tyrosine
kinase inhibitors; immunomodulating agents
Psychiatric drugs Clozapine, olanzapine; chlorpromazine, risperidone, lithium;
methylphenidate; tricyclic antidepressants;
Other drugs Chloroquine; all-trans retinoic acid; antiretroviral agents;
phenothiazines
Toxic and overload
Ethanol Risk proportional to entity and duration of alcohol intake.
Frequent good response after withdrawal
Cocaine, amphetamines, ecstasy Chronic users
Other toxic Arsenic; cobalt; anabolic/androgenic steroids
Iron overload Transfusions; haemochromatosis
Nutritional deficiency
Selenium deficiency Rare, high frequency in some regions in China (Keshan disease)
Thiamine deficiency (Beri-Beri) Favoured by malnutrition, alcohol abuse. High-output dilated
cardiac failure
Zinc and copper deficiency Possible contributors to DCM
Carnitine deficiency Paediatric patients
Electrolyte disturbance
Hypocalcemia, hypophosphatemia
Endocrinology
Hypo- and hyper-thyroidism
Cushing/addison disease
Phaeocromocytoma
Acromegaly
Diabetes mellitus
Continued
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can be very mild or in some circumstances absent in spite of the
presence of clinically significant myocardial disease on cardiac
MRI, radionuclide studies or EMB.3,35 For these reasons, we believe
that clinical diagnosis and ultimately treatment can be improved by
updating the criteria for diagnosis in relatives of DCM patients and
the creation of a new category of hypokinetic non-dilated cardiomyop-
athy (HNDC).
The clinical spectrum of DCM is described in Figure 1. In many in-
dividuals—for example, relatives who are mutation carriers or ex-
hibit anti-heart antibodies—there is a preclinical phase without
cardiac expression that subsequently progresses towards mild car-
diac abnormalities, such as isolated LV dilatation (present in 25%
of relatives of familial DCM and which predicts development of a full
phenotype during following years),9– 11 or arrhythmogenic features
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Continued
Group Subtype disease or agent Comments
Infection
Viral (including HIV), bacterial (including Lyme
disease), mycobacterial, fungal, parasitic
(Chagas disease)
DCM caused by infectious myocarditis.
Atrio-ventricular block (AVB) in Lyme disease. Chagas’
disease: DCM develops after a long latent infection
Auto-immune diseases
Organspecific
Giant-cell myocarditis (GCM) Multinucleated giant cell; frequent AV block and ventricular
arrhythmia
Inflammatory DCM DCM caused by biopsy-proven, non-infectious myocarditis
Not organ specific
Polymyositis/dermatomyositis; Churg–Strauss
syndrome; Wegener’s granulomatosis; systemic
lupus erythematosus, sarcoidosis
In cardiac sarcoidosis there is granulomatous myocarditis; AV
block is frequent DCM is possible but uncommon in these
diseases
Peripartum Risk factors: multiparity, African descent, familial DCM,
autoimmunity
Figure 1 Description of the clinical spectrum of DCM. LV abn, left ventricle abnormality. DCM can be further classified as ND or D (non-
dilation/dilation) or NH or H (non-hypokinetic/hypokinetic) or mut+ (mutation carrier) or AHA+ (anti-heart autoantibody positive) or
A/CD (arrhythmia/conduction defect).
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(ventricular or supra-ventricular arrhythmia or conduction defects)
that can be observed in myocarditis3,36 or in the early phase of gen-
etic diseases such as lamin A/C and neuromuscular disorders.15 The
overt phase of systolic dysfunction is usually associated with LV dila-
tation, but this may be absent in some cases causing diagnostic con-
fusion (described in Lamin A/C gene mutation carriers37,38 and also
in some patients without a known genetic cause13). For this reason
we propose a new category of HNDC.
Definitions
Dilated cardiomyopathy
Left ventricular or biventricular systolic dysfunction and dilatation that are
not explained by abnormal loading conditions or coronary artery disease.
Notes:
Systolic dysfunction is defined by abnormal LV ejection fraction,20 mea-
sured using any modality and shown either by two independent imaging
modalities or on two distinct occasions by the same technique, preferably
echocardiograohy or CMR.20
Left ventricular dilatation is defined by LV end-diastolic (ED) volumes or
diameters .2SD from normal according to normograms (Z scores .2
standard deviations) corrected by body surface area (BSA) and age, or
BSA and gender. Normograms for echocardiographic volumes and dia-
meters are available for adults and children39 and can be calculated using
web-based calculators (www.parameterz.com) and by an App (Parame-
terZ an for iPhone/ipad platform).40
Hypokinetic non-dilated cardiomyopathy
Left ventricular or biventricular global systolic dysfunction without dilata-
tion (defined as LVEF, 45%), not explained by abnormal loading condi-
tions or coronary artery disease.
Note:
Strictly decreased LVEF is mandatory in index patient with HNDC since
no combination with dilatation is mandatory for the diagnosis.
Diagnostic criteria in relatives
As the relatives of patients with DCM or with HNDC can develop
overt disease, they should be considered for clinical and genetic
screening.8,34 However, clinical testing in relatives often reveals
mild non-diagnostic abnormalities that overlap with normal vari-
ation or mimic changes seen in other more common diseases
such as hypertension and obesity. In this statement, we propose
three new diagnostic categories for relatives of cases with either
DCM or HNDC who undergo screening, which takes into account
whether a definite causative mutation has been identified as well
as the presence of clinical features that are associated with the
development of overt DCM (major criteria) or are suggestive of
incomplete disease expression (minor criteria). We acknowledge
that evidence to support the use of minor criteria in this context
is based on small studies or DCM caused by specific mutations.30
By using genotype to lower the diagnostic threshold, but not to
characterize the phenotypic status per se, we also acknowledge
genotype as a static, continuously present susceptibility factor that
differs from more dynamic phenotypic expressions.
Recommendation 1: Definition of disease in a relative
(briefly summarized in Figure 3)
Definite disease
Meets criteria for DCM or HNDC
Probable disease
When:
(i) One major criterion (from Box 1) plus at least one minor
criterion (from Box 1)
OR
(ii) One major criterion (from Box 1) plus carrying the causative
mutation identified in the proband
Possible disease
When:
(i) Two minor criteria (from Box 1)
OR
(ii) One minor criterion (from Box 1) plus carrying the causative
mutation identified in the proband
(iii) One major criterion (from Box 1) but without any minor cri-
terion and without genetic data within the family
Recommendation 2: Definition of familial disease
Definition of familial disease in the absence of conclusive molecular
genetic information in a family:
(1) When two or more individuals (first or second degree relatives)
have DCM or HNDC fulfilling diagnostic criteria for ‘definite’
disease
OR
(2) In the presence of an index patient fulfilling diagnostic criteria
for DCM/HNDC and a first-degree relative with autopsy-
proven DCM and sudden death1 at ,50 years of age
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Box 1 Diagnostic criteria for relatives
MAJOR
1. Unexplained decrease of LVEF ≤50% but .45%
OR
2. Unexplained LVED dilatation (diameter or volume) according to
nomograms (LVED diameter/volume .2SD + 5% since this more
specific echocardiographic criterion was used in studies that demonstrated
the predictive impact of isolated dilatation in relatives)a
MINOR
1. Complete LBBB, or AV block (PR.200 ms or higher degree AV block)
2. Unexplained ventricular arrhythmia (.100 ventricular premature
beats per hour in 24 h or non-sustained ventricular tachycardia, ≥3
beats at a rate of ≥120 beats per minute).
3. Segmental wall motion abnormalities in the left ventricle in the
absence of intraventricular conduction defect
4. Late enhancement (LGE) of non-ischaemic origin on cardiac
magnetic resonance imaging.
5. Evidence of non-ischaemic myocardial abnormalities (inflammation,
necrosis and/or fibrosis) on EMB.
6. Presence of serum organ-specific and disease-specific AHA by one
or more autoantibody tests.
Note: aFeature shown either by two independent imaging modalities or on two
distinct occasions by the same technique
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Overlap with arrhythmogenic right
ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) or ar-
rhythmogenic cardiomyopathy (AVC) is a progressive heart muscle
disorder defined by replacement of cardiomyocytes by fat and fibro-
sis that is associated with structural and functional abnormalities of
the right ventricle (RV). It is usually inherited as an autosomal-
dominant trait caused by mutations in genes encoding for desmo-
somal proteins, although a number of other genetic and non-genetic
phenocopies (e.g. myocarditis) are recognized. While RV disease
defines the condition, there are a number of features that can over-
lap with DCM as defined in this statement. In particular, LV involve-
ment ranging from scars on CMR to severe LV dilation and systolic
impairment which has been reported in up to 76% of patients. There
is also overlap in causation—for example, desmosomal gene muta-
tions are relatively common in patients with a clinical diagnosis of
DCM.17 Although the degree to which both DCM and ARVC coex-
ist within families is poorly characterized, the presence of right ven-
tricular abnormalities such as dilatation and ventricular ectopy of
right ventricular origin in relatives of patients with DCM may be a
diagnostic red flag for the presence of familial disease.35 Similarly,
the presence of LV dysfunction in a relative of a patient with un-
equivocal ARVC does not necessarily imply a different disease. Myo-
carditis with or without a DCM phenotype may mimic ARVC and
EMB may be required for differential diagnosis.35
Diagnostic work-up in index
patients
Considering the broad spectrum of disorders that cause DCM, a
systematic approach can be helpful (Figure 2) in identifying and man-
aging uncommon but clinically important forms of DCM. The
principles of this process are described elsewhere in another pos-
ition statement from this Working Group.8 In brief, the systematic
search for diagnostic clues or ‘red flags’ can suggest particular disor-
ders and guide rational selection of additional diagnostic tests. Im-
portantly, each stage of the clinical pathway from history to
molecular testing has value.
Some of the most important diagnostic clues are described in
Supplementary material online, Table S2. Clinical workup starts
with personal and family history, physical examination, and a focused
analysis of ECG and echocardiography (Figure 2). Identification of
clinical features suggestive of specific diseases should then lead to
a second-level diagnostic work-up that may include biochemical
analyses, MRI, EMB, and genetic testing. Diagnostic work-up should
take into account the age of the patient (see Supplementary material
online, Figure S1).
The role of genetic testing in cardiomyopathies has been the sub-
ject of a previous position Statement of this Working Group.34
Once a mutation is identified, and its pathogenic role is established,
then this may have multiple impacts since the information is able to
confirm the genetic origin and mode of inheritance, may be used for
guidance of therapy and can be used for family cascade screening
and early diagnosis.
Recommendation 3: Diagnostic work-up
(1) Coronary artery disease should be excluded in patients more
than 35 years of age, or before 35 years if there are significant
personal coronary artery disease (CAD) risk factors or a family
history of early CAD.
(2) First-line laboratory testing should include creatine kinase (CK),
renal function, urine analysis for proteinuria, liver function tests,
haemoglobin and white blood cell count, serum iron, ferritin,
calcium, phosphate, natriuretic peptides and thyroid stimulating
hormone.
Figure 2 Diagnostic work-up for aetiology assessment.
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(3) Second-line diagnostics should be targeted to the suspected
aetiology.
(4) Cardiac magnetic resonance (CMR) may be useful for assessment
of ventricular size and function and for tissue characterization.3
(5) In patients with clinically suspected myocarditis3 (EMB [includ-
ing histology, immunohistology, and polymerase chain reaction
(PCR)] for infectious agents is recommended. Endomyocardial
biopsy should also be considered when there is clinical suspi-
cion of storage or metabolic diseases that cannot be confirmed
by other means.
(6) Cardiac screening with echocardiography and ECG is recom-
mended in all first degree-relatives of an index patient with
DCM, irrespective of family history.
(7) Genetic testing is recommended in the presence of a familial
form of DCM OR in sporadic DCM with clinical clues suggestive
of a particular/rare genetic disease (such as atrio-ventricular
block or CK elevation).
(8) Genetic testing should be oriented by clinical diagnostic clues
when present, and should be restricted to genes known to
cause DCM. The use of next-generation sequencing (NGS)
for the analysis of very large panels of genes, including titin,
may be considered when the family structure permits segrega-
tion analysis (i.e. several patients with DCM and DNA available).
Aetiology-directed management
and therapy
The identification of a specific underlying cause for DCM can have
profound consequences for clinical management. For example,
identification of a definite genetic cause should lead to genetic coun-
selling and screening of relatives and in some specific circumstances
prompt regular monitoring for complications such as conduction
disease. It also has significant consequences for advice on contra-
ception and reproduction (see Supplementary material online, Table
S3) and in a number of examples, early intervention with ICDs, life-
style modification, and specific drug therapy may also be necessary.
General advice on the management of heart failure can be found in
current ESC guidelines for chronic heart failure.20 In DCM caused by
LMNA mutations, risk assessment also involves gender-specific risk
as described elsewhere.41
Relatives with minor cardiac abnormalities such as LV enlarge-
ment are at increased risk of DCM development11 and may benefit
from early medical treatment (although this has not yet demon-
strated by placebo controlled trials).42 We provide a summary of
advice for the management of pregnancy in Supplementary material
online, Table 3A and B.
Familial dilated cardiomyopathy
and follow-up of relatives
Recommendation 4
† In the context of familial DCM, cardiac screening with Echo and
ECG (+ Holter monitoring depending upon main phenotype in
proband) should be performed in all first degree-relatives (from
childhood) and should be repeated every 2–3 years if cardiovas-
cular tests are normal, every year if minor abnormalities are de-
tected, whenever symptoms develop. Search in a relative for
conduction defects or arrhythmia which may be an early
Figure 3 Overview of dilated cardiomyopathy criteria in probands and relatives.
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presentation of DCM, especially in the context of an LMNA gene
mutation.
Recommendation 5
† When a causative mutation has been identified in a DCM patient,
then predictive genetic testing should be offered to first-degree
relatives in order to guide cardiac follow-up.
Recommendation 6
† When a definite causative LMNA mutation is identified, early in-
dication for primary prevention by ICD implantation should be
considered (guided by the risk factors as detailed elsewhere).43,44
Inflammatory dilated
cardiomyopathy
Recommendation 7
† In familial and non-familial pedigrees with biopsy-proven inflam-
matory DCM in the index case, cardiac-specific autoantibody
(AHA) test at baseline and at follow-up should be considered
in symptom-free relatives with or without cardiac abnormalities
(e.g. ECG, echocardiography, CMR).
† Non-invasive cardiac screening with echocardiography and ECG
may be more frequent in relatives with cardiac autoantibodies.
† Immunomodulatory and/or immunosuppressive therapy in
biopsy-proven non-infectious inflammatory DCM should be
considered.
† Physical activity should be restricted in DCM with underlying
biopsy-proven active phase of myocarditis.
Summary
In this paper the Working Group on Myocardial and Pericardial Dis-
ease proposes a revised definition of DCM (see also Figure 3) in an
attempt to bridge the gap between our recent understanding of the
disease spectrum and its clinical presentation in relatives, which is
key for early diagnosis and the institution of potential preventative
measures. We also provide practical hints to identify subsets of
the DCM syndrome where aetiology-directed management has
great clinical relevance.
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